Abstract
Suppressor of cytokine signaling (SOCS)-1 is an essential regulator of many cytokine signaling pathways, including those upregulated in the inflamed colonic mucosa of patients with ulcerative colitis. We sought to investigate whether the functional SOCS-1 −1478CA>del polymorphism is associated with UC susceptibility and its disease phenotype in a Turkish clinical sample. A total of 104 subjects were enrolled in a case–control study (52 UC cases and 52 controls). The SOCS-1 −1478CA>del polymorphism was genotyped using a polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) method. The odds ratio of the del allele for UC relative to the CA allele was not significant (OR = 1.04, 95 % CI 0.59–1.82, P = 0.88). These results did not change after adjustment for age and sex in multivariable regression analysis (OR = 1.07, 95 % CI 0.42–1.69, P = 0.73). When the SOCS-1 −1478CA>del polymorphism was analyzed among UC patients according to continuous disease and non-continuous disease, the del allele was not associated with disease recurrence (OR = 1.56, 95 % CI 0.78–4.56, P = 0.83). Furthermore, when we divided UC patients into two groups according to a previous history of colectomy, we found no significant effect of the del allele (OR = 1.94, 95 % CI 0.55–5.61, P = 0.91). Taken together, these findings suggest that SOCS-1 −1478CA>del polymorphism does not contribute to UC susceptibility and its disease phenotype in Turkish subjects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ford AC, Moayyedi P, Hanauer SB (2013) Ulcerative colitis. BMJ 346:f432
Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ (2012) Ulcerative colitis. Lancet 380:1606–1619
Danese S, Fiocchi C (2011) Ulcerative colitis. N Engl J Med 365:1713–1725
Magro F, Rodrigues A, Vieira AI, Portela F, Cremers I, Cotter J, Correia L, Duarte MA, Tavares ML, Lago P, Ministro P, Peixe P, Lopes S, Garcia EB (2012) Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis 18:573–583
Travis SP, Higgins PD, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O’Morain C, Panés J, Sturm A, Reinisch W, Kamm MA, D’Haens G (2011) Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 34:113–124
Di Sabatino A, Biancheri P, Rovedatti L, Macdonald TT, Corazza GR (2012) Recent advances in understanding ulcerative colitis. Intern Emerg Med 7:103–111
Cavanaugh JA, Pavli P (1997) Ulcerative colitis: a genetic disease? Baillieres Clin Gastroenterol 11:1–15
Mayberry JF (1985) Some aspects of the epidemiology of ulcerative colitis. Gut 26:968–974
Orholm M, Fonager K, Sørensen HT (1999) Risk of ulcerative colitis and Crohn’s disease among offspring of patients with chronic inflammatory bowel disease. Am J Gastroenterol 94:3236–3238
Thompson AI, Lees CW (2011) Genetics of ulcerative colitis. Inflamm Bowel Dis 17:831–848
Latiano A, Annese V (2011) Genetics and ulcerative colitis: what are the clinical implications? Curr Drug Targets 12:1383–1389
Ki Ohya, Kajigaya S, Yamashita Y, Miyazato A, Hatake K, Miura Y, Ikeda U, Shimada K, Ozawa K, Mano H (1997) SOCS-1/JAB/SSI-1 can bind to and suppress tec protein-tyrosine kinase. J Biol Chem 272:27178–27182
Piganis RA, De Weerd NA, Gould JA, Schindler CW, Mansell A, Nicholson SE, Hertzog PJ (2011) Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem 286:33811–33818
Losman JA, Chen XP, Hilton D, Rothman P (1999) Cutting edge: sOCS-1 is a potent inhibitor of IL-4 signal transduction. J Immunol 162:3770–3774
Olsen T, Cui G, Goll R, Husebekk A, Florholmen J (2009) Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol 44:727–735
Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ (1998) Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis 4:285–290
Harada M, Nakashima K, Hirota T, Shimizu M, Doi S, Fujita K, Shirakawa T, Enomoto T, Yoshikawa M, Moriyama H, Matsumoto K, Saito H, Suzuki Y, Nakamura Y, Tamari M (2007) Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. Am J Respir Cell Mol Biol 36:491–496
Chan HC, Ke LY, Chang LL, Liu CC, Hung YH, Lin CH, Li RN, Tsai WC, Liu HW, Yen JH (2010) Suppressor of cytokine signaling 1 gene expression and polymorphisms in systemic lupus erythematosus. Lupus 19:696–702
Christophi GP, Rong R, Holtzapple PG, Massa PT, Landas SK (2012) Immune markers and differential signaling networks in ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis 18:2342–2356
Podolsky DK (1991) Inflammatory bowel disease (2). N Engl J Med 325:1008–1016
Langholz E, Munkholm P, Davidsen M, Binder V (1994) Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107:3–11
Emanuele E, Fontana JM, Minoretti P, Geroldi D (2010) Preliminary evidence of a genetic association between chromosome 9p21.3 and human longevity. Rejuvenation Res 13:23–26
Chan HC, Ke LY, Liu CC, Chang LL, Tsai WC, Liu HW, Yen JH (2010) Increased expression of suppressor of cytokine signaling 1 mRNA in patients with rheumatoid arthritis. Kaohsiung J Med Sci 26:290–298
Conflict of interest
The authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hartavi, M., Nak, S.G., Oral, B. et al. No association between the SOCS-1 −1478CA/del polymorphism and ulcerative colitis in Turkish subjects. Mol Biol Rep 41, 6505–6508 (2014). https://doi.org/10.1007/s11033-014-3533-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-014-3533-7